Novartis v. Taro Pharmaceuticals: PROMACTA® Eltrombopag Patent Action Dismissed
Novartis AG and Novartis Pharmaceuticals Corporation filed suit against Taro Pharmaceuticals in the District of New Jersey asserting five patents covering PROMACTA® eltrombopag olamine tablets. The case closed after 126 days via voluntary dismissal without prejudice under Rule 41(a)(1)(A)(i), with each party bearing its own costs.
Novartis drops five-patent PROMACTA® suit against Taro after 126 days
On July 11, 2025, Novartis AG and Novartis Pharmaceuticals Corporation filed an infringement action against Taro Pharmaceuticals in the U.S. District Court for the District of New Jersey before Judge Georgette Castner. The complaint asserted five patents — US8052994B2, US8052993B2, US8071129B2, US8062665B2, and US8828430B2 — all covering eltrombopag olamine formulations underlying the branded thrombopoietin receptor agonist PROMACTA®. The suit was triggered by Taro’s ANDA filing seeking approval for generic eltrombopag olamine tablets in 12.5 mg, 25 mg, 50 mg, and 75 mg strengths.
The action closed on November 14, 2025, when Novartis filed a voluntary dismissal pursuant to Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure. The dismissal was filed before any answer or motion for summary judgment was served by Taro, consistent with the procedural requirements of Rule 41(a)(1)(A)(i). The filing specifies dismissal of all claims without prejudice, and the cost allocation — each party bearing its own fees — suggests no negotiated financial exchange was recorded on the public docket.
A 126-day case duration in ANDA patent litigation is notably brief; typical Hatch-Waxman cases in New Jersey run considerably longer before reaching a substantive resolution. The speed of dismissal, combined with the without-prejudice designation, suggests the parties may have reached a private licensing or settlement arrangement outside the public record, or that Novartis reassessed its enforcement strategy against Taro specifically. What remains unknown is whether a confidential consent agreement, patent licence, or market entry date was negotiated, none of which would appear on the public docket.
Filing to Voluntary dismissal in 126 days
126-day case duration — resolved before substantive motion practice is typical in ANDA litigation
Voluntarily dismissed: what Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i) allows plaintiff to exit before defendant responds
Under Rule 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order if filed before the opposing party serves an answer or a motion for summary judgment. This is a unilateral procedural right. The dismissal here carries a without-prejudice designation, meaning Novartis preserves the ability to refile the same claims. No judicial merits ruling was issued.
Procedural exit — no merits rulingThe public record says ‘without prejudice’ — but the distinction matters
A dismissal without prejudice leaves the door open for Novartis to refile the same infringement claims against Taro in future. A dismissal with prejudice would have extinguished those claims permanently. The filed notice explicitly states without prejudice, though the underlying commercial rationale — whether a licence, consent decree, or strategic retreat — is not disclosed on the public docket.
Without prejudice confirmedTaro avoids a merits finding — but faces ongoing uncertainty
Taro Pharmaceuticals receives no declaratory judgment of non-infringement or invalidity. The without-prejudice dismissal means Novartis could reassert these five patents if Taro launches its generic eltrombopag olamine product. Unless a private agreement governs Taro’s launch rights, the generic manufacturer faces continued patent exposure until the asserted patents expire or are otherwise resolved.
No invalidity finding for TaroGeneric eltrombopag market entry timeline remains uncertain
PROMACTA® (eltrombopag olamine) is indicated for chronic immune thrombocytopenia and other serious haematological conditions. The without-prejudice dismissal leaves the commercial launch window for Taro’s generic unresolved publicly. Competitors and payers tracking generic entry should note that no court-validated launch date or patent expiry milestone has been established by this proceeding.
Generic launch timeline unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Pharmaceutical innovator and PROMACTA® rights holder — holder of US8052994B2 and four related eltrombopag olamine patentsSearch in Eureka ↗ |
| Defendant | Taro Pharmaceuticals | Individual | Generic pharmaceutical manufacturer seeking ANDA approval for eltrombopag olamine tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Cynthia Stencel Betz | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Mark M. Makhail | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Presiding judge | Judge Georgette Castner | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) and records dismissal of all claims without prejudice, with each side absorbing its own costs. The without-prejudice designation is legally significant: it carries no res judicata effect, meaning Novartis retains full standing to refile the same five-patent infringement claims against Taro. The mutual cost-bearing provision suggests neither party conceded advantage. No claim construction, validity finding, or injunctive relief ruling was issued, leaving the substantive patent questions entirely open.
US8052994B2 — Eltrombopag olamine pharmaceutical formulations
The five asserted patents — US8052994B2, US8052993B2, US8071129B2, US8062665B2, and US8828430B2 — all derive from application families filed around 2009 (US12/607305, US12/607291, US12/607284, US12/607320) and a later continuation (US13/272367), covering pharmaceutical formulations of eltrombopag olamine, the active ingredient in PROMACTA®. Eltrombopag is a small-molecule thrombopoietin receptor agonist used to stimulate platelet production in patients with chronic immune thrombocytopenia (ITP) and other haematological conditions.
This patent family represents a classic Hatch-Waxman formulation thicket — multiple patents covering compositional variants of the same drug substance, collectively extending the period during which generic entry requires patent clearance. For any generic manufacturer or biosimilar developer working in the thrombopoietin receptor agonist space, the breadth and number of these patents creates meaningful FTO complexity. The US8828430B2 continuation filing, with its later priority date, suggests Novartis actively prosecuted supplemental coverage and may hold additional related patents not asserted in this action.
Should your team run an FTO against the eltrombopag olamine patent family?
Any pharmaceutical company developing or licensing generic eltrombopag olamine tablets — or formulation scientists working on thrombopoietin receptor agonist oral dosage forms — should treat this five-patent cluster as a live FTO risk. The without-prejudice dismissal does not invalidate or narrow any of the five asserted patents. ANDA applicants and 505(b)(2) filers in the eltrombopag space remain exposed until expiry, inter partes review, or a disclosed licence agreement resolves these claims.
PatSnap Eureka’s FTO Search Agent can map the full continuation and divisional landscape around the US12/607305 application family, identify related pending applications that may issue as additional patents, and surface prior art relevant to validity challenges. For IP counsel advising on generic launch timing or paragraph IV certification strategy, Eureka’s claim-level analysis can accelerate the scope assessment needed before any ANDA submission.
Run a freedom-to-operate analysis on US8052994B2 to assess your product’s exposure
Run FTO in Eureka →Similar eltrombopag and ANDA formulation patent cases in New Jersey
Cases involving Hatch-Waxman ANDA challenges to eltrombopag olamine formulation patents litigated in the District of New Jersey before Judge Castner and peer courts.
What this case signals for the eltrombopag and ANDA litigation landscape
A five-patent ANDA suit resolved in 126 days without a merits ruling raises pointed questions about enforcement strategy and private deal-making in branded pharmaceutical IP.
Without-prejudice exits in ANDA cases often signal private licensing activity
When an innovator voluntarily dismisses an ANDA infringement suit before the defendant even answers, the most commercially plausible explanation is a negotiated resolution — a licence, consent decree, or agreed launch date — concluded outside the public record. Patent teams monitoring Novartis enforcement strategy should treat this dismissal as a potential indicator of a confidential agreement.
Five-patent assertion stacks create leverage — and settlement risk
Asserting five formulation patents simultaneously against a single ANDA applicant maximises pre-trial leverage but also increases the cost and complexity of litigation for both sides. The speed of this dismissal is consistent with the defendant or plaintiff concluding that the economics of full Hatch-Waxman litigation did not justify continuation — a pattern seen across New Jersey ANDA dockets.
Novartis v Taro — key questions answered
Novartis asserted five patents: US8052994B2, US8052993B2, US8071129B2, US8062665B2, and US8828430B2. All five cover pharmaceutical formulations of eltrombopag olamine, the active ingredient in Novartis’s branded PROMACTA® thrombopoietin receptor agonist tablets.
Novartis filed a voluntary dismissal under Rule 41(a)(1)(A)(i) on November 14, 2025. The public filing does not disclose the commercial reason. The without-prejudice designation and mutual cost-bearing provision are consistent with a private settlement, licence, or strategic decision, but no such agreement appears on the public docket.
The dismissal was explicitly stated as without prejudice in the filed notice. This means Novartis retains the right to refile the same infringement claims against Taro in future. No merits determination was made and no res judicata bar applies to the asserted patents.
PROMACTA® is Novartis’s branded eltrombopag olamine tablet, a thrombopoietin receptor agonist approved for chronic immune thrombocytopenia and other serious haematological conditions. Taro filed an ANDA seeking to market generic versions in 12.5 mg, 25 mg, 50 mg, and 75 mg strengths, triggering Novartis’s infringement action under the Hatch-Waxman Act.
Yes. A Rule 41(a)(1)(A)(i) voluntary dismissal without prejudice carries no claim preclusion effect. Novartis may refile all five patent claims against Taro at any time before the patents expire, provided no separate agreement between the parties bars such action. Taro received no invalidity ruling or non-infringement judgment from this proceeding.
PatSnap Eureka searches patents and litigation data to answer instantly.